Alphamine
Alphamine, licence 80102157: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Performance Enhancing Supplements LLC dba Physique Enhancing Science
- NPN or DIN-HM
- 80102157
- Status
- Active licence
- Licence date
- 25 June 2020
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Olea europaea Source : Feuille Extract : Matériel brut sec Extraction ratio : 25.0:1.0 Dry plant equivalent : 2000.0 mg Potency : 5.0 mg 3,4-Dihydroxyphenylethanol | 80.0 mg | Not calculated |
| Olea europaea Source : Feuille Potency : 20.0 mg Oleuropein | Not specified | Not calculated |
| 1,3,7-triméthylxanthine Source : Caféine | 125.0 mg | Not calculated |
| 1,3,7-triméthylxanthine Source : Dicaffeine malate | 125.0 mg | Not calculated |
| Acide 1H-pyrrolo(2,3-f)quinoline-2,7,9-tricarboxylique, 4,5-dihydro-4,5-dioxo- Source : Pyrroloquinoline quinone | 5.0 mg | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium, Gélatine, Stéarate de magnésium, Dioxyde de titane, Bleu FD&C n° 1, Rouge FD&C N° 40
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | 1.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Helps (temporarily) to promote alertness and wakefulness, and to enhance cognitive performance. Helps (temporarily) to support/promote mental sharpness/alertness. Helps (temporarily) to relieve fatigue, to promote endurance, and to enhance motor performance. Helps (temporarily) to enhance (physical) energy. Helps (temporarily) to reduce tiredness and fatigue. Source of/Provides Antioxidants. An antioxidant that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Helps to temporarily increase basal metabolic rate/thermogenesis.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Stop use if hypersensitivity/allergy occurs.
Source
Official Health Canada record, licence 80102157
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.